Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.
Dr. Aditya Bardia: Hello. I'm Aditya Bardia, a breast medical oncologist at Massachusetts General Hospital, Harvard Medical School, Boston.
Today, we'll review potential role of Elacestrant for the treatment of metastatic ER-positive HER2-negative breast cancer. We'll start with an overview of metastatic ER-positive breast cancer, the current landscape, and then review the EMERALD trial with I Elacestrant for metastatic ER-positive breast cancer.
Metastatic ER-positive HER2-negative breast cancer represents a subset of metastatic disease. Metastatic disease refers to patients who have evidence of breast cancer outside of the breast in the bones, liver, or other organs. ER-positive refers to tumors that express estrogen receptors and do not have HER2 amplification so therefore HER2-negative. In general, tissue biopsy is the mainstay for diagnosis of metastatic ER-positive HER2-negative breast cancer. It helps with confirmation of the diagnosis and also evaluation of the receptors.
Endocrine-based therapy is the mainstay of management of metastatic ER-positive HER2-negative breast cancer. It's also the mainstay of management for early ER-positive HER2-negative breast cancer. For metastatic ER-positive HER2-negative metastatic breast cancer, the first line of therapy includes endocrine therapy with a CDK4/6 inhibitor. Usually, it's aromatase inhibitor, but in specific situations fulvestrant is used as the first line endocrine therapy in combination with a CDK4/6 inhibitor. Options for CDK4/6 inhibitors include ribociclib, abemaciclib, and palbociclib. We've seen improvement in overall survival with the use of endocrine therapy plus abema, endocrine therapy plus ribociclib in the first-line setting.
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Uncovering the Neighborhood Influence on Breast Cancer Mortality
March 8th 2024Samilia Obeng-Gyasi, MD, MPH, delved into the background and findings of this study assessing the correlation between neighborhood opportunity, allostatic load, and all-cause mortality among patients with breast cancer.
Read More